Published in AIDS on September 02, 2005
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry (2010) 1.73
Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. J Neurovirol (2008) 1.64
HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis (2009) 1.64
HIV-associated neurocognitive disorder. Lancet Infect Dis (2013) 1.60
Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med (2011) 1.42
Pattern of neuropsychological performance among HIV positive patients in Uganda. BMC Neurol (2007) 1.35
Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis (2012) 1.35
Neuropsychological assessment of HIV-infected populations in international settings. Neuropsychol Rev (2009) 1.31
Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis (2012) 1.31
Prevalence and risk factors of major depressive disorder in HIV/AIDS as seen in semi-urban Entebbe district, Uganda. BMC Psychiatry (2011) 1.22
Neuropsychiatric and socioeconomic status impact antiretroviral adherence and mortality in rural Zambia. Am J Trop Med Hyg (2011) 1.21
Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc (2010) 1.20
Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology (2009) 1.20
HIV-1 effects on neuropsychological performance in a resource-limited country, Zambia. AIDS Behav (2011) 1.12
Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature. AIDS (2013) 1.10
Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol (2007) 1.10
Validity of an interviewer-administered patient health questionnaire-9 to screen for depression in HIV-infected patients in Cameroon. J Affect Disord (2012) 1.08
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. J Neurovirol (2016) 1.08
Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaoundé-Cameroon. J Neurol Sci (2009) 1.07
Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology (2011) 1.07
The prevalence and characteristics of suicidality in HIV/AIDS as seen in an African population in Entebbe district, Uganda. BMC Psychiatry (2012) 1.05
HIV DNA and dementia in treatment-naïve HIV-1-infected individuals in Bangkok, Thailand. Int J Med Sci (2006) 1.04
Psychological distress and adherence to highly active anti-retroviral therapy (HAART) in Uganda: a pilot study. Afr Health Sci (2009) 1.03
Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria. J Neurovirol (2012) 1.00
HIV-associated neurocognitive disorders (HAND) in a South Asian population - contextual application of the 2007 criteria. BMJ Open (2012) 0.98
A systematic review of the screening accuracy of the HIV Dementia Scale and International HIV Dementia Scale. PLoS One (2013) 0.97
Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav (2011) 0.96
Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa. J Neurovirol (2011) 0.95
Neuroimaging markers of human immunodeficiency virus infection in South Africa. J Neurovirol (2012) 0.95
Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale. J Neuroimmune Pharmacol (2013) 0.95
Lessons learned developing a diagnostic tool for HIV-associated dementia feasible to implement in resource-limited settings: pilot testing in Kenya. PLoS One (2012) 0.93
Validity of cognitive screens for HIV-associated neurocognitive disorder: a systematic review and an informed screen selection guide. Curr HIV/AIDS Rep (2013) 0.92
HIV-1 nef protein structures associated with brain infection and dementia pathogenesis. PLoS One (2011) 0.91
Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology (2012) 0.91
Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review. BMC Public Health (2014) 0.91
A review of opioid prescribing practices and associations with repeat opioid prescriptions in a contemporary outpatient HIV clinic. Pain Pract (2011) 0.90
Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana. PLoS One (2011) 0.89
Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand. J Neuroimmunol (2008) 0.89
Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol (2011) 0.89
Identification of an abbreviated test battery for detection of HIV-associated neurocognitive impairment in an early-managed HIV-infected cohort. PLoS One (2012) 0.89
HIV-associated neurocognitive disorders. J Mol Psychiatry (2014) 0.89
Screening for HIV-associated dementia in South Africa: potentials and pitfalls of task-shifting. AIDS Patient Care STDS (2011) 0.88
Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders. J Neurovirol (2013) 0.86
A Smartphone App to Screen for HIV-Related Neurocognitive Impairment. J Mob Technol Med (2014) 0.86
Comparison of the Minimental State Examination Scale and the International HIV Dementia Scale in Assessing Cognitive Function in Nigerian HIV Patients on Antiretroviral Therapy. AIDS Res Treat (2012) 0.84
Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. Metab Brain Dis (2014) 0.84
Normative scores for a brief neuropsychological battery for the detection of HIV-associated neurocognitive disorder (HAND) among South Africans. BMC Res Notes (2010) 0.84
An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China. J Neurovirol (2012) 0.84
Neurologic Complications and Considerations in HIV-Infected Persons. Curr Infect Dis Rep (2013) 0.83
HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project. HIV Med (2014) 0.82
Neuropsychiatric complications of aging with HIV. J Neurovirol (2012) 0.82
Study to assess the prevalence, nature and extent of cognitive impairment in people living with AIDS. Indian J Psychiatry (2012) 0.82
Prevalence and factors associated with probable HIV dementia in an African population: a cross-sectional study of an HIV/AIDS clinic population. BMC Psychiatry (2013) 0.82
Longitudinal neuropsychological test performance among HIV seropositive individuals in Uganda. J Neurovirol (2013) 0.82
HIV subtype is not associated with dementia among individuals with moderate and advanced immunosuppression in Kampala, Uganda. Metab Brain Dis (2014) 0.82
HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study. PLoS One (2014) 0.81
Prevalence of HIV-Associated Neurocognitive Disorder (HAND) among Patients Attending a Tertiary Health Facility in Northern Nigeria. J Int Assoc Provid AIDS Care (2014) 0.81
A perspective on the proposal for neurocognitive disorder criteria in DSM-5 as applied to HIV-associated neurocognitive disorders. Neuropsychiatry (London) (2011) 0.81
Neurology and the Global HIV Epidemic. Semin Neurol (2014) 0.81
Exploring the utility of the Montreal Cognitive Assessment to detect HIV-associated neurocognitive disorder: the challenge and need for culturally valid screening tests in South Africa. Clin Neuropsychol (2013) 0.81
Translational challenges in targeting latent HIV infection and the CNS reservoir problem. J Neurovirol (2014) 0.80
Cognitive dysfunction among HIV positive and HIV negative patients with psychosis in Uganda. PLoS One (2012) 0.80
A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder. J Neurovirol (2013) 0.80
Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients. J Clin Exp Neuropsychol (2010) 0.79
Diagnostic accuracy of the International HIV Dementia Scale and HIV Dementia Scale: A meta-analysis. Exp Ther Med (2012) 0.79
Efficacy of an alcohol-focused intervention for improving adherence to antiretroviral therapy (ART) and HIV treatment outcomes - a randomised controlled trial protocol. BMC Infect Dis (2014) 0.79
Training needs and evaluation of a neuro-HIV training module for non-physician healthcare workers in western Kenya. J Neurol Sci (2011) 0.79
Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. J Neurovirol (2013) 0.79
Prevalence, characteristics and correlates of a positive-dementia screen in patients on antiretroviral therapy in Bamenda, Cameroon: a cross-sectional study. BMC Neurol (2013) 0.79
Factors related to HIV-associated neurocognitive impairment differ with age. J Neurovirol (2014) 0.78
An international screening tool for HIV dementia. AIDS (2005) 0.78
Increases in CSF dopamine in HIV patients are due to the dopamine transporter 10/10-repeat allele which is more frequent in HIV-infected individuals. J Neural Transm (Vienna) (2013) 0.78
HIV-associated neurocognitive disorders: perspective on management strategies. Drugs (2013) 0.77
Structural gray matter change early in male patients with HIV. Int J Clin Exp Med (2014) 0.77
Evaluation of a Cognitive Rehabilitation Protocol in HIV Patients with Associated Neurocognitive Disorders: Efficacy and Stability Over Time. Front Behav Neurosci (2015) 0.76
Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda. J Neurovirol (2016) 0.76
Interaction Effects between HIV and Aging on Selective Neurocognitive Impairment. J Neuroimmune Pharmacol (2017) 0.75
Selective developmental alterations in The HIV-1 transgenic rat: Opportunities for diagnosis of pediatric HIV-1. J Neurovirol (2016) 0.75
Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic. PLoS One (2016) 0.75
Use of Western Neuropsychological Test Battery in Detecting HIV-Associated Neurocognitive Disorders (HAND) in Zambia. AIDS Behav (2016) 0.75
Cultural adaptation of a cognitive-behavioural intervention to improve adherence to antiretroviral therapy among people living with HIV/AIDS in Zimbabwe: Nzira Itsva. J Health Psychol (2016) 0.75
Prevalence of HIV Associated Neurocognitive Deficit among HIV Positive People in Ethiopia: A Cross Sectional Study at Ayder Referral Hospital. Ethiop J Health Sci (2017) 0.75
Depression and diagnosis of neurocognitive impairment in HIV-positive patients. Braz J Med Biol Res (2016) 0.75
A cluster randomised controlled trial protocol of an adapted intervention for alcohol use disorders in people living with HIV and AIDS: impact on alcohol use, general functional ability, quality of life and adherence to HAART. BMC Psychiatry (2017) 0.75
HIV psychiatry in the era of combined antiretroviral therapy: top five issues. J Int AIDS Soc (2015) 0.75
A short tool to screen HIV-infected patients for mild neurocognitive disorders - a pilot study. BMC Psychol (2014) 0.75
Prevalence and Correlates of HIV-Associated Neurocognitive Disorders (HAND) in Northwestern Nigeria. Neurol Res Int (2015) 0.75
Watering flowers in the rain: The elusive nature of executive dysfunction in HIV. J Neurosci Rural Pract (2011) 0.75
Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization-case study. J Neurovirol (2017) 0.75
Effect of HIV infection on time to recovery from an acute manic episode. HIV AIDS (Auckl) (2010) 0.75
The association between symptoms of mental disorders and health risk behaviours in Vietnamese HIV positive outpatients: a cross-sectional study. BMC Public Health (2017) 0.75
Cognitive Impairment among Persons of Rural Background Living with Human Immunodeficiency Virus Infection on Antiretroviral Therapy: A Study from a Tertiary Care Centre of North India. J Neurosci Rural Pract (2016) 0.75
Improving detection of HIV-associated cognitive impairment: Comparison of the International HIV Dementia Scale and a Brief Screening Battery. J Acquir Immune Defic Syndr (2016) 0.75
Recognizing cognitive and psychiatric changes in the post-highly active antiretroviral therapy era. Can J Infect Dis Med Microbiol (2012) 0.75
Physical function, grip strength and frailty in people living with HIV in sub-Saharan Africa: systematic review. Trop Med Int Health (2017) 0.75
HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol (2017) 0.75
Reliability of White Matter Microstructural Changes in HIV Infection: Meta-Analysis and Confirmation. AJNR Am J Neuroradiol (2017) 0.75
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res (2012) 9.02
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
Stroke and encephalopathy after cardiac surgery: an update. Stroke (2005) 2.91
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
A call to action for comprehensive HIV services for men who have sex with men. Lancet (2012) 2.70
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon (2003) 2.39
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Lancet (2008) 2.31
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology (2012) 2.30
Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27
A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis (2005) 2.25
Impact of nonoperative treatment, vertebroplasty, and kyphoplasty on survival and morbidity after vertebral compression fracture in the medicare population. J Bone Joint Surg Am (2013) 2.24
Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis (2013) 2.18
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol (2009) 2.14
Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults. Trop Med Int Health (2012) 2.08
Acceptance of routine testing for HIV among adult patients at the medical emergency unit at a national referral hospital in Kampala, Uganda. AIDS Behav (2006) 2.08
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther (2006) 2.02
Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav (2012) 2.01
Watershed strokes after cardiac surgery: diagnosis, etiology, and outcome. Stroke (2006) 1.98
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (2011) 1.90
The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain (2004) 1.90
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
HIV counseling and testing practices at an urban hospital in Kampala, Uganda. AIDS Behav (2006) 1.83
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther (2012) 1.79
Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol (2004) 1.79
Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry (2010) 1.73
Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). J Clin Exp Neuropsychol (2003) 1.70
Using mobile phones to improve clinic attendance amongst an antiretroviral treatment cohort in rural Uganda: a cross-sectional and prospective study. AIDS Behav (2010) 1.69
Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS (2002) 1.68
Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav (2011) 1.66
Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol (2005) 1.65
HIV-associated sensory neuropathies. AIDS (2002) 1.65
Evaluating sleep and cognition in HIV. J Acquir Immune Defic Syndr (2013) 1.64
HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis (2009) 1.64
Delirium after coronary artery bypass graft surgery and late mortality. Ann Neurol (2010) 1.63
Primary mania versus HIV-related secondary mania in Uganda. Am J Psychiatry (2006) 1.62
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
The effects of hospital and surgeon volume on postoperative complications after LumbarSpine surgery. Spine (Phila Pa 1976) (2011) 1.61
Dysphagia after anterior cervical decompression and fusion: prevalence and risk factors from a longitudinal cohort study. Spine (Phila Pa 1976) (2005) 1.58
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read (2002) 1.56
HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS (2010) 1.56
Peripheral neuropathy in HIV: prevalence and risk factors. AIDS (2011) 1.53
Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology (2004) 1.49
Neuropsychological test profile differences between young and old human immunodeficiency virus-positive individuals. J Neurovirol (2007) 1.49
Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature (2006) 1.48
Reproducibility of tDCS Results in a Randomized Trial: Failure to Replicate Findings of tDCS-Induced Enhancement of Verbal Fluency. Cogn Behav Neurol (2016) 1.47
Length of red cell unit storage and risk for delirium after cardiac surgery. Anesth Analg (2014) 1.46
Diagnostic utility of the subjective peripheral neuropathy screen in HIV-infected persons with peripheral sensory polyneuropathy. AIDS Read (2005) 1.46
Intraoperative hemoglobin levels and transfusion independently predict stroke after cardiac operations. Ann Thorac Surg (2011) 1.45
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging (2004) 1.44
Normative data for determining significance of test-retest differences on eight common neuropsychological instruments. Clin Neuropsychol (2004) 1.44
Quantitative MR spectroscopic imaging of brain lesions in patients with AIDS: correlation with [11C-methyl]thymidine PET and thallium-201 SPECT. Acad Radiol (2002) 1.43
Subjective memory symptoms in surgical and nonsurgical coronary artery patients: 6-year follow-up. Ann Thorac Surg (2009) 1.43
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol (2008) 1.40